Objective To investigate the effect of Avastin (bevacizumab) combined with preoperative FOLFOX neoadjuvant chemotherapy on the prognosis of patients with locally advanced rectal cancer (LARC).MethodsA total of 80 cases of patients with LARC treated with total mesorectal excision (TME) in our hospital from January 2013 to January 2016 were randomly divided into the control group and the observation group, 40 cases in each group.The control group were treated with preoperative FOLFOX chemotherapy while the observation group were treated with bevacizumab injection, based on the treatment in the control group.21 days was a cycle of chemotherapy, and both groups were treated for at least 4 cycles.After 6 cycles of chemotherapy, operation was carried out, following TEM principle.The short-term and long-term prognosis, rate of R0 resection, the incidence of postoperative complications and side effects of chemotherapy were compared between the two groups.ResultsThere was no significant difference between the two groups in the good response rate of chemotherapy, the rate of R0 resection, the incidence of postoperative complications, the 1-year and 3-year survival rates and 1-year disease-free survival rate.The incidence rates of gastrointestinal reactions and bone marrow suppression in the observation group were 52.5% and 52.5%, respectively while in the control group were 25.0% and 20.0%, respectively (P<0.05), but there was no significant difference in the incidence rates of grade Ⅲ~Ⅳ gastrointestinal reaction and bone marrow suppression between the observation group and the control group (5.0% and 15.0% vs 2.5% and 5.0%).The 3-year disease-free survival rate of the observation group was higher than that of the control group (82.5% vs 60.0%) (P<0.05).ConclusionThe application of bevacizumab combined with preoperative FOLFOX chemotherapy in the treatment of LARC can improve the 3-year disease-free survival rate, without increasing postoperative adverse reactions and serious side effects of chemotherapy.

Objective: To discuss the affect of glycosylated hemoglobin (HbA1c) level for the onset of nonalcoholic fatty liver disease (NAFLD) in cohort population. Methods: An epidemiological survey of the relationship between HbA1c and NAFLD conducted in 2012 was based at cohort baseline, and three follow-up sessions conducted in 2013, 2014 and 2015. In total 2 811 subjects were included in the study after exclusion of NAFLD patients at baseline and those who lost their lives due to relocation, and death. The Cox proportional hazard model was used to analyze the relationship between glycosylated hemoglobin and other risk factors of NAFLD. Continuous variables were compared using the t-test or the Mann-Whitney test. χ ²-test was used for the measurement of categorical data. Results: A total of 2 811 subjects with mean age of 59 (58.2±9.8) years old, including 1 664 males and 1 147 females. Age, waist circumference, body mass index, systolic blood pressure, γ-glutamyltransferase and fasting blood glucose level of HbA1c abnormal group were higher than normal group. The incidence of NAFLD in the abnormal HbA1c level group (25.4%) was higher than normal group (14.9 %), and diastolic blood pressure, high-density lipoprotein cholesterol was lower than normal group and the differences were statistically significant. During the three follow-up intervals, there were 440 new cases of NAFLD, consisting 285 males and 155 females with cumulative incidence of 15.7% (440/2 811). Multivariate Cox regression analysis showed that patients with elevated HbA1c had a higher risk of developing NAFLD (HR 1.796; 95% CI 1.335~2.418; P < 0.01), and the increased HbA1c level after adjustment for gender, age, and metabolic syndrome-related factors remained an independent risk factors for NAFLD (HR 1.580; 95.0% CI 1.161-2.152; P < 0.01). Conclusion An elevated HbA1c levels have a positive predictive value for the onset of NAFLD.

OBJECTIVETo observe the effect of ginsenoside Rg1 on behavior and hippocampal amino acids in depressive-like rats.

METHODSD rats were randomly divided into 5 groups: control, model, fluxetine, low dose ginsenoside Rg1 and high dose of ginsenoside Rg1. The chronic unpredictable mild stress (CUMS) was performed to induce depressive-like animal model. Fluxetine group was orally given fluxetine in dose of 10 mg x kg(-1) for 21 days, low dose ginsenoside Rg1 group was orally given ginsenoside Rg1 in dose of 20 mg x kg(-1) for 21 days, high dose ginsenoside Rg1 group was orally given ginsenoside Rg1 in dose of 40 mg x kg(-1) for 21 days. The control and model group was orally given saline for 21 days. The sucrose consumption was detected before and after the CUMS procedure. The horizontal and vertical activities of rats were determined by open-field test. HPLC was adopted to detect the contents of amino acids in hippocampus.

RESULTThe sucrose consumption, horizontal and vertical activities in CUMS rats were decreased compared with those in control group. Compared with control group, the contents of glutamate (Glu) and aspartate (Asp) in hippocampus of CUMS group were increased, while the gamma amino butyric acid (GABA) and taurine (Tau) were decreased. Ginsenoside Rg1 treatment significantly increased the CUMS-induced decrease in sucrose consumption, horizontal and vertical activities. Administrated with ginsenoside Rg1 also decreased Glu and Asp and increased the GABA and Tau in hippocampus in a dose dependent manner.

CONCLUSIONGinsenoside Rg1 could alleviate the behavior changes of depressive-like rats, which might be related to regulate the levels of amino acids in hippocampus during CUMS and prevent the neuro-toxicity of excitatory amino acids.

Amino Acids ; metabolism ; Animals ; Behavior, Animal ; drug effects ; Depression ; drug therapy ; metabolism ; psychology ; Disease Models, Animal ; Ginsenosides ; administration & dosage ; Hippocampus ; drug effects ; metabolism ; Humans ; Male ; Rats ; Rats, Sprague-Dawley

Objective:To investigate the potential mechanism by which Brucella suis vaccine strain S2 induces the apoptosis of BV-2 microglia cells, and to discover new protein targets for neurobrucellosis treatment. Methods:BV-2 microglia cells were treated with Brucella suis vaccine strain S2 for 0, 3, 6, 12 and 24 h. Western blot assay and RT-qPCR were performed to detect the expression of p-JNK and p53 at protein and mRNA levels in BV-2 microglia cells. Cell apoptosis was measured by flow cytometry. Immunofluorescence was used to analyze nuclear p-JNK. Results:Brucella suis vaccine strain S2 could promote the expression of p-JNK and p53 at both protein and mRNA levels and increase nuclear p-JNK in BV-2 microglia cells. Moreover, it could also induce the apoptosis of BV-2 microglia cells. Conclusions:Brucella suis vaccine strain S2 could promote the apoptosis of BV-2 microglia cells through activating JNK and promoting p53 expression.